There were as many billion-dollar brands in 2017 as there have been in any other calendar year despite the cratering effects of massive patent cliffs in 2012 and 2015.

Acceleron Pharma’s investigational drug luspatercept hit its Phase III endpoints as a treatment for patients with myelodysplastic syndrome (MDS), a disorder where the bone marrow does not produce enough healthy blood cells.

Amgen Inc. and The University of Texas MD Anderson Cancer Center announced two multi-year collaborative research deals for a broad range of cancer therapeutics. The cancers studied will include leukemia, myelodysplastic syndromes (MDS), multiple myeloma, small-cell lung cancer, and other non-lung cancers with small-cell histologies.

Summit, NJ-based Celgene and Cambridge, Mass.-based bluebird bio released updated data from an ongoing Phase I clinical trial of bb2121 at the American Society of Hematology (ASH) Annual Meeting in Atlanta.

Vitamin C may “tell” faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers. This is the finding of a study led by researchers from Perlmutter Cancer Center at NYU Langone Health, and published online August 17, 2017, in the journal Cell.

Helsinn Group and MEI Pharma inked an exclusive licensing, development and commercialization deal to develop and market Pracinostat to treat AML.

February 18, 2016By Mark Terry, Breaking News Staff   Newton, Pa.-based Onconova Therapeutics (ONTX), in an effort to cut costs and hold on to its cash, indicated it is cutting 17 percent of its workforce, including the company’s chief financial officer and president of research and development. The company’s chief executive officer, Ramesh Kumar, […]

January 22, 2016By Alex Keown, Breaking News Staff   PHILADELPHIA – TetraLogic Pharmaceuticals (TLOG) plans to eliminate two-thirds of its employees by next month following the failure of a Phase II treatment for high-risk patients with myelodysplastic syndromes earlier this month. The company filed a regulatory report with the U.S. Securities and Exchange Commission […]